Journal Information
Vol. 16. Issue 3.
Pages 419-430 (May - June 2010)
Share
Share
Download PDF
More article options
Vol. 16. Issue 3.
Pages 419-430 (May - June 2010)
Full text access
Factores de risco de displasia broncopulmonar em cinco unidades portuguesas de cuidados intensivos neonatais
Risk factors for bronchopulmonary dysplasia in five Portuguese neonatal intensive care units
Visits
1005
Hercília Guimarães1,6, Gustavo Rocha1,6, Gabriela Vasconcellos1,6, Elisa Proença2,6, Maria Luísa Carreira3,6, Maria do Rosário Sossai4,6, Benvinda Morais4,6, Isabel Martins5,6, Teresa Rodrigues5,6, Milton Severo5,6
1 Maternidade Júlio Dinis (Director: Dr. José Pombeiro), Porto
2 Hospital de Santo António (Director Drª. Paula Cristina Fernandes), Porto
3 Hospital Fernando Fonseca (Director Drª Rosalina Barrosos), Lisboa
4 Hospital Pedro Hispano (Drª Agostinha Souto), Porto
5 Serviço de Epidemiologia (Director Professor Henrique de Barros), Faculty of Medicine of Porto University, Portugal
6 Hospital de S. João (Director: Professora Doutora Hercília Guimarães), Porto
Related content
Rev Port Pneumol. 2010;16:69310.1016/S2173-5115(10)70071-3
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumo

A displasia broncopulmonar (DBP) é multifactorial. Prematuridade, doença da membrana hialina, oxigénio, ventilação mecânica, inflamação e canal arterial são alguns dos factores na sua patogénese

Objectivo

Avaliar a prevalência da DBP e seus factores de risco em cinco unidades portuguesas, para implementar boas práticas no tratamento deste doentes.

Material e métodos

256 recém-nascidos (RN) com idade gestacional (IG) <30 semanas e/ou peso <1250g internados em cinco unidades portuguesas, entre 2004 e 2006, foram estudados. Foi recolhida a informação clínica dos processos. A DBP foi definida como a necessidade de oxigénio às 36 semanas de idade pós-conceptional.

Resultados

A prevalência da DBP foi de 12,9%. O seu risco diminuiu de 46% por semana de IG e de 39% por 100g de peso. O risco de DBP foi maior entre os RN com baixo peso (OR adj=0,73, 95% CI=0,57–0,95), doença da membrane hialina grave (OR adj=9,85, 95% CI=1,05–92,35), com sépsis (OR adj=6,22, 95% CI=1,68–23,02), com maior duração de ventilação (42 vs 3 dias, respectivamente nos RN com e sem DBP, p<0,001) e maior duração de FiO2>0,30 (85 vs 5 dias, respectivamente nos doentes com e sem DBP, p<0,001).

Comentários

Os factores de risco de DBP mais relevantes foram o baixo peso, a doença da membrana hialina grave, a duração da ventilação mecânica e da oxigenoterapia e a sépsis. A implementação das boas práticas para reduzir a lesão pulmonar nos RN deve ser dirigida para melhorar as práticas que reduzem estes factores de risco.

Palavras chave:
Displasia broncopulmonar
recém-nascidos pré-termo
unidades de cuidados intensivos neonatais
doença da membrana hialina
ventilação mecânica
oxigenoterapia
factores de risco
boas práticas
Abstract

The pathogenesis of bronchopulmonary dysplasia (BPD) is clearly multifactorial. Specific pathogenic risk factors are prematurity, respiratory distress, oxygen supplementation, mechanical ventilation (MV), inflammation, patent ductus arteriosus (PDA), etc.

Aim

To evaluate BPD prevalence and to identify risk factors for BPD in five Portuguese Neonatal Intensive Care Units in order to develop better practices the management of these newborns.

Material and methods

256 very low birth weight infants with gestational age (GA) <30 weeks and/or birthweight (BW) <1250g admitted in five Portuguese NICUs, between 2004 and 2006 were studied. A protocol was filled in based on clinical information regis- tered in the hospital charts. BPD was defined as oxygen dependency at 36 weeks of postconceptional age.

Results

BPD prevalence was 12.9% (33/256). BPD risk decreased 46% per GA week and of 39% per 100g BW. BPD risk was significantly higher among newborns with low BW (adj OR=0.73, 95% CI=0.57-0.95), severe hyaline membrane disease (adj OR=9.85, 95% CI=1.05-92.35), and those with sepsis (adj OR=6.22, 95% CI=1.68-23.02), those with longer duration on ventilatory support (42 vs 3 days, respectively in BPD and no BPD patients, p<0.001) and longer duration of FiO2>0.30 (85 vs 5 days, respectively in BPD and no BPD patients, p<0.001).

Comments

The most relevant risk factors were low birth weight, severe hyaline membrane disease, duration of respiratory support and oxygen therapy, and nosocomial sepsis. The implementation of potentially better practices to reduce lung injury in neonates must be addressed to improve practices to decrease these risk factors.

Key words:
Bronchopulmonary dysplasia
preterm infants
neonatal intensive care
prematurity
hyaline membrane disease
mechanical ventilation
oxygen therapy
risk factors
better practices
Full text is only aviable in PDF
Bibliography
[1.]
I.R.S. Sosenko, E. Bancalari.
New developments in the presentation, pathogenesis, epidemiology and prevention of bronchopulmonary dysplasia.
The Newborn Lung Eduardo Bancalari, pp. 187-207
[2.]
H.L. Halliday, C.P. O'Neil.
What is the evidence for drug therapy in the prevention and management of bronchopulmonary dysplasia?.
The newborn lung, pp. 208-232
[3.]
R.A. Ehrenkranz, M.C. Walsh, B.R. Vohr, A.H. Jobe, L.L. Wright, A.A. Fanaroff, L.A. Wrage, K. Poole.
National Institutes of Child Health and Human Development Neonatal Research Network Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.
Pediatrics, 116 (2005), pp. 1353-1360
[4.]
W.H. Northway Jr., R.C. Rosan, D.Y. Porter.
Pulmonary disease following respirator therapy of hyaline-membrane disease.Bronchopulmonary dysplasia.
N Engl J Med, 16 (1967), pp. 357-368
[5.]
E. Bancalari, G.E. Abdenour, R. Feller, J. Gannon.
Bronchopulmonary dysplasia: clinical presentation.
J Pediatr, 95 (1979), pp. 819-823
[6.]
A.T. Shennan, M.S. Dunn, A. Ohlsson, K. Lennox, E.M. Hoskins.
Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period.
Pediatrics, 82 (1988), pp. 527-532
[7.]
A.H. Jobe, E. Bancalari.
Bronchopulmonary dysplasia.
Am J Respi Crit Care Med, 163 (2001), pp. 1723-1729
[8.]
H. MacDonald.
American Academy of Pediatrics. Committee on fetus and newborn. Perinatal care at the threshold of viability.
Pediatrics, 110 (2002), pp. 1024-1027
[9.]
J.L. Ballard, J.C. Khoury, K. Wedig, L. Wang, B.L. Eilers- Walsman, R. Lipp.
New ballard score, expanded to include extremely premature infants.
J Pediatr, 119 (1991), pp. 417-423
[10.]
A.J. Rudolph, C.A. Smith.
Idiopathic respiratory distress syndrome of the newborn.
J Pediatr, 57 (1960), pp. 905-921
[11.]
M.C. Walsh, R.M. Kliegman.
Necrotizing enterocolitis: treatment based on staging criteria.
Ped Clin N Am, 33 (1986), pp. 179-201
[12.]
An International Classification of Retinopathy of Prematurity.
Pediatrics, 74 (1984), pp. 127-133
[13.]
The International Classification of Retinopathy of Prematurity revisited. International Committee for the Classification of Retinopathy of Prematurity.
Arch Ophthalmol, 123 (2005), pp. 991-999
[14.]
L.A. Papile, J. Burstein, R. Burstein.
Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweights less than 1500g.
J Pediatr, 92 (1978), pp. 529-534
[15.]
L. de Vries, J.M. Rennie.
Preterm brain injury.
Textbok of neonatology, 3th edition, pp. 1252-1270
[16.]
E. Bancalari, N. Claure, I.R. Sosenko.
Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition.
Semin Neonatol, 8 (2003), pp. 63-71
[17.]
M.C. Walsh, Q. Yao, P. Gettner, E. Hale, M. Collins, A. Hensman, R. Everette, N. Peters, N. Miller, G. Muran, K. Auten, N. Newman, G. Rowan, C. Grisby, K. Arnell, L. Miller, B. Ball, G. McDavid.
National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates.
Pediatrics, 114 (2004), pp. 1305-1311
[18.]
M. Walsh, W. Engle, A. Laptook, S.N. Kazzi, S. Buchter, M. Rasmussen, Q. Yao.
National Institute of Child Health and Human Development Neonatal Research Network. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved?.
Pediatrics, 116 (2005), pp. 857-861
[19.]
VLBW infants in Portugal. National Multicenter Study 1996–2000. Portuguese Neonatal Network. Bial Award of Clinical Medicine 2002. ISBN 972-99224-0-3.
[20.]
A. Valcamonico, P. Accorsi, C. Sanzeni, P. Martelli, P. La Boria, A. Cavazza, T. Frusca.
Mid- and long-term outcome of extremely low birth weight (ELBW) infants: an analysis of prognostic factors.
Matern Fetal Neonatal Med, 20 (2007), pp. 465-471
[21.]
C.P. Speer.
Inflammation and bronchopulmonary dysplasia: a continuing story.
Semin Fetal Neonatal Med, 11 (2006), pp. 354-362
[22.]
C.L. Bose, C.E. Dammann, M.M. Laughon.
Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate.
Arch Dis Child Fetal Neonatal Ed, 93 (2008), pp. F455-F461
[23.]
P. Groneck, J. Schmale, V. Soditt, H. Stützer, B. Götze- Speer, C.P. Speer.
Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease.
Pediatr Pulmonol, 31 (2001), pp. 331-338
[24.]
D.G. Sweet, H.L. Halliday.
Modeling and remodeling of the lung in neonatal chronic lung disease: implications for therapy.
Treat Respir Med, 4 (2005), pp. 347-359
[25.]
G. Rocha, E. Proença, C. Quintas, T. Rodrigues, H. Guimarães.
Chorioamnionitis and lung damage in the extremely low birth weight infant.
Rev Port Pneumol, 3 (2007), pp. 745-754
[26.]
Been JV, Zimmermann LJ. Histologic chorioamnionitis and respiratory outcome in preterm infants. Arch Dis Child Fetal Neonatal; Ed. 2009 Jan 8. [Epub ahead of print.]
[26.]
L. Gortner, I. Reiss, A. Hilgendorff.
Bronchopulmonary dysplasia and intrauterine growth restriction.
[27.]
K.A. Marks, B. Reichman, A. Lusky, E. Zmora.
Israel Neonatal Network. Fetal growth and postnatal growth failure in very-low-birthweight infants.
Acta Paediatr, 95 (2006), pp. 236-242
[28.]
L. Gortner, A. Hilgendorff, T. Bähner, M. Ebsen, I. Reiss, S. Rudloff.
Hypoxia-induced intrauterine growth retardation: effects on pulmonary development and surfactant protein transcription.
Biol Neonate, 88 (2005), pp. 129-135
[29.]
G. Kewitz, S. Wudel, H. Hopp, W. Hopfenmüller, M. Vogel, I. Roots.
Below median birth weight in appropriate- for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia.
J Perinat Med, 36 (2008), pp. 359-364
[30.]
D. Sweet, G. Bevilacqua, V. Carnielli, G. Greisen, R. Plavka, O. Didrik Saugstad, U. Simeoni, C.P. Speer, A. Valls-I-Soler, H. Halliday.
Working Group on Prematurity of the World Association of Perinatal Medicine. European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome.
J Perinat Med, 35 (2007), pp. 175-186
[31.]
K. Burch, W. Rhine, R. Baker, F. Litman, J.W. Kaempf, E. Schwarz, S. Sun, N.R. Payne, P.J. Sharek.
Implementing potentially better practices to reduce lung injury in neonates.
Pediatrics, 111 (2003), pp. e432-e436
[32.]
R. Ramanathan.
Optimal ventilatory strategies and surfactant to protect the preterm lungs.
Neonatology, 93 (2008), pp. 302-308
[33.]
R. Ramanathan, S. Sardesai.
Lung protective ventilatory strategies in very low birth weight infants.
J Perinatol., 28 (2008), pp. S41-S46
[34.]
K. Bohlin, B. Jonsson, A.S. Gustafsson, M. Blennow.
Continuous positive airway pressure and surfactant.
Neonatology, 93 (2008), pp. 309-315
[35.]
D. Patel, A. Greenough.
Does nasal CPAP reduce bronchopulmonary dysplasia (BPD)?.
Acta Paediatr, 97 (2008), pp. 1314-1317
[36.]
O.D. Saugstad.
Take a breath--but do not add oxygen (if not needed).
Acta Paediatr, 96 (2007), pp. 798-800
[37.]
O.D. Saugstad, S. Ramji, R.F. Soll, M. Vento.
Resuscitation of newborn infants with 21% or 100% oxygen: an updated systematic review and meta-analysis.
Neonatology, 94 (2008), pp. 176-182
[38.]
W. Tin, S. Gupta.
Optimum oxygen therapy in preterm babies.
Arch Dis Child Fetal Neonatal; Ed., 92 (2007), pp. F143-F147
[39.]
STOP-ROP Multicenter Study Group.
Supplemental therapeutic oxygen for pretreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial. I: Primary outcomes.
Pediatrics, 105 (2000), pp. 295-310
[40.]
A. Sola.
Oxygen in neonatal anesthesia: friend or foe?.
Curr Opin Anaesthesiol, 21 (2008), pp. 332-339
[41.]
T.P. Stevens, E.W. Harrington, M. Blennow, R.F. Soll.
Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
Cochrane Database Syst Rev, 17 (2007), pp. CD003063
[42.]
W. Oh, B.B. Poindexter, R. Perritt, J.A. Lemons, C.R. Bauer, R.A. Ehrenkranz, B.J. Stoll, K. Poole, L.L. Wright.
Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.
J Pediatr, 147 (2005), pp. 786-790
[43.]
Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, McKinley L, Tucker R, Vohr BR. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2008; 28(2):123-128.
[44.]
E.F. Bell, M.J. Acarregui.
Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev, 1 (2008), pp. CD000503
[45.]
Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128(4):470-478.
[46.]
M. Liljedahl, L. Bodin, J. Schollin.
Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia.
Acta Paediatr, 93 (2004), pp. 211-215
[47.]
D. Bassler, B.J. Stoll, B. Schmidt, E.V. Asztalos, R.S. Roberts, C.M. Robertson, R.S. Sauve.
Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection.
Trial of Indomethacin Prophylaxis in Preterms Investigators. Pediatrics, 123 (2009), pp. 313-318
[48.]
M. Moro, J. Pérez-Rodriguez, J. Figueras-Aloy, C. Fernández, E. Doménech, R. Jiménez, V. Pérez-Sheriff, J. Quero, V. Roques.
Predischarge morbidities in extremely and very low-birth-weight infants in spanish neonatal units.
Am J Perinatol, (2008), pp. 17
[49.]
P. Lundqvist, K. Källén, I. Hallström, L.H. Westas.
Trends in outcomes for very preterm infants in the southern region of Sweden over a 10-year period.
Acta Paediatr, 98 (2009), pp. 648-653
[50.]
First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns. Golombek SG, Sola A, Baquero H, Borbonet D, Cabañas F, Fajardo C, Goldsmit G, Lemus L, Miura E, Pellicer A, Pérez JM, Rogido M, Zambosco G, van Overmeire B, Primer Grupo de Consenso Clínico SIBEN (Golombek SG, Sola A, Clyman R, van Overmeire B, Goldsmit G, Natta D, Zambosco G, Miura E, Péerez JM, Weissheimer C, Baquero H, García Harker J,Oviedo Barrantes AN, Morgues M, Tapia JL, Domínguez F, Majano M, Cabañas F, Pellicer A, Cruz H, Fajardo C, Rogido M, Lemus L, Origel AV, Lacarruba JM, Lee M, Tresierra J, Guimarães H, Bustos R, Borbonet D, Perales JL. An Pediatr 2008; 69(5):454-481.
[51.]
A. Ohlsson, R. Walia, S. Shah.
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Cochrane Database Syst Rev, 23 (2008), pp. CD003481
[52.]
R. Mosalli, K. Alfaleh.
Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants.
Cochrane Database Syst Rev, 23 (2008), pp. CD006181
[53.]
D. McCurnin, S. Seidner, L.Y. Chang, N. Waleh, M. Ikegami, J. Petershack, B. Yoder, L. Giavedoni, K.H. Albertine, M.J. Dahl, Z.M. Wang, R.I. Clyman.
Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung.
Pediatrics, 121 (2008), pp. 945-956
[54.]
W. Tin, T.E. Wiswell.
Adjunctive therapies in chronic lung disease: examining the evidence.
Semin Fetal Neonatal Med, 13 (2008), pp. 44-52
[55.]
N.R. Payne, M. LaCorte, P. Karna, S. Chen, M. Finkelstein, J.P. Goldsmith, J.H. Carpenter.
Breathsavers Group, Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative.
Pediatrics, 118 (2006), pp. S73-S77
[56.]
N.R. Payne, M. LaCorte, S. Sun, P. Karna, M. Lewis- Huns tiger, J.P. Goldsmith, Breathsavers Group.
Evaluation and development of potentially better practices to reduce bronchopulmonary dysplasia in very low birth weight infants.
Pediatrics, 118 (2006), pp. S65-S72
[57.]
P.J. Sharek, R. Baker, F. Litman, J. Kaempf, K. Burch, E. Schwarz, S. Sun, N.R. Payne.
Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates.
Pediatrics, 111 (2003), pp. e426-e431
Copyright © 2010. Sociedade Portuguesa de Pneumologia
Download PDF
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?